切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2025, Vol. 14 ›› Issue (02) : 187 -196. doi: 10.3877/cma.j.issn.2095-3232.2025033

专家论坛

肝内胆管癌手术与综合治疗
丁志文1, 赵一鸣1, 王鲁1,()   
  1. 1. 200032 上海,复旦大学附属肿瘤医院肝脏外科 复旦大学上海医学院肿瘤学系
  • 收稿日期:2024-11-23 出版日期:2025-04-10
  • 通信作者: 王鲁
  • 基金资助:
    国家自然科学基金(NSFC2081)徐汇区卫计委重要疾病联合攻关(XHLHGG202103)湖北陈孝平科技发展基金会项目(CXPJJH123001-2317)

Progress in surgical and systematic treatment of intrahepatic cholangiocarcinoma

Zhiwen Ding1, Yiming Zhao1, Lu Wang1,()   

  1. 1. Department of Hepatic Surgery, Fudan University Shanghai Cancer Center,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Received:2024-11-23 Published:2025-04-10
  • Corresponding author: Lu Wang
引用本文:

丁志文, 赵一鸣, 王鲁. 肝内胆管癌手术与综合治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 187-196.

Zhiwen Ding, Yiming Zhao, Lu Wang. Progress in surgical and systematic treatment of intrahepatic cholangiocarcinoma[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 187-196.

肝内胆管癌是肝原发恶性肿瘤中的一种,其发病率在我国呈逐年升高的趋势。外科手术切除是患者获得长期生存的最主要手段,近些年以免疫治疗为代表的系统治疗迅速发展,对外科手术治疗也产生了重要的影响。在此,我们回顾了肝内胆管癌手术治疗的最新进展,重点探讨了以手术为基础的辅助治疗、新辅助治疗等综合治疗。

Intrahepatic cholangiocarcinoma (ICC) is one of primary malignant tumors of the liver,and its incidence rate has been elevated year by year in China.Surgical resection is the major treatment for ICC patients to obtain long-term survival.In recent years, systematic therapy, especially immunotherapy, has developed rapidly and exerted significant impact on surgical treatment.In this article, the latest progress in surgical treatment of ICC was reviewed, focusing on surgery-based systematic treatment, such as adjuvant therapy and neoadjuvant therapy, etc.

[1]
Zhang H, Yang T, Wu M, et al.Intrahepatic cholangiocarcinoma:Epidemiology, risk factors, diagnosis and surgical management[J].C a n c e r L e t t, 2 0 1 6, 3 7 9(2): 1 9 8-2 0 5.D O I: 1 0.1 0 1 6/j.canlet.2015.09.008.
[2]
Valle JW, Kelley RK, Nervi B, et al.Biliary tract cancer[J].Lancet,2021, 397(10272): 428-444.DOI: 10.1016/s0140-6736(21)00153-7.
[3]
Izquierdo-Sanchez L, Lamarca A, La Casta A, et al.Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry[J].J Hepatol, 2022, 76(5): 1109-1121.DOI: 10.1016/j.jhep.2021.12.010.
[4]
Chaiteerakij R, Harmsen WS, Marrero CR, et al.A new clinically based staging system for perihilar cholangiocarcinoma[J].Am J Gastroenterol, 2014, 109(12): 1881-1890.DOI: 10.1038/ajg.2014.327.
[5]
Glantzounis GK, Tokidis E, Basourakos SP, et al.The role of portal vein embolization in the surgical management of primary hepatobiliary cancers:a systematic review[J].Eur J Surg Oncol, 2017, 43(1): 32-41.DOI: 10.1016/j.ejso.2016.05.026.
[6]
Amin MBES, Greene F, Byrd DR, et al.AJCC cancer staging manual [M].8th ed.New York: Springer, 2017.
[7]
Kubo S, Shinkawa H, Asaoka Y, et al.Liver cancer study group of Japan clinical practice guidelines for intrahepatic cholangiocarcinoma[J].Liver Cancer, 2022, 11(4): 290-314.DOI: 10.1159/000522403.
[8]
Okabayashi T, Yamamoto J, Kosuge T, et al.A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables[J].Cancer, 2001, 92(9):2374-2383.DOI: 10.1002/1097-0142(20011101)92: 9<2374: aidcncr1585>3.0.co;2-l.
[9]
Spolverato G, Bagante F, Weiss M, et al.Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma[J].J Surg Oncol, 2017, 115(6): 696-703.DOI: 10.1002/jso.24569.
[10]
Cheng Z, Lei Z, Si A, et al.Modifications of the AJCC 8th edition staging system for intrahepatic cholangiocarcinoma and proposal for a new staging system by incorporating serum tumor markers[J].HPB,2019, 21(12): 1656-1666.DOI: 10.1016/j.hpb.2019.05.010.
[11]
Lamarca A, Santos-Laso A, Utpatel K, et al.Liver metastases of intrahepatic cholangiocarcinoma: implications for an updated staging system[J].Hepatology, 2021, 73(6): 2311-2325.DOI: 10.1002/hep.31598.
[12]
Farges O, Fuks D, Boleslawski E, et al.Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma:a multicenter study by the AFC-IHCC-2009 study group[J].Ann Surg, 2011, 254(5): 824-829;discussion830.DOI: 10.1097/SLA.0b013e318236c21d.
[13]
Esnaola NF, Meyer JE, Karachristos A, et al.Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma[J].Cancer, 2016, 122(9): 1349-1369.DOI: 10.1002/cncr.29692.
[14]
Amini N, Ejaz A, Spolverato G, et al.Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis[J].J Surg Oncol, 2014, 110(2):163-170.DOI: 10.1002/jso.23605.
[15]
European Association for the Study of the Liver.EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma[J].J Hepatol, 2023, 79(1): 181-208.DOI:10.1016/j.jhep.2023.03.010.
[16]
Lamarca A, Barriuso J, Chander A, et al.18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis[J].J Hepatol, 2019,71(1): 115-129.DOI: 10.1016/j.jhep.2019.01.038.
[17]
Moris D, Palta M, Kim C, et al.Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians[J].CA Cancer J Clin, 2023,73(2): 198-222.DOI: 10.3322/caac.21759.
[18]
Mazzaferro V, Gorgen A, Roayaie S, et al.Liver resection and transplantation for intrahepatic cholangiocarcinoma[J].J Hepatol,2020, 72(2): 364-377.DOI: 10.1016/j.jhep.2019.11.020.
[19]
Utada M, Ohno Y, Tamaki T, et al.Long-term trends in incidence and mortality of intrahepatic and extrahepatic bile duct cancer in Japan[J].J Epidemiol, 2014, 24(3): 193-199.DOI: 10.2188/jea.je20130122.
[20]
Yamamoto M, Ariizumi SI.Surgical outcomes of intrahepatic cholangiocarcinoma[J].Surg Today, 2011, 41(7): 896-902.DOI:10.1007/s00595-011-4517-z.
[21]
Si A, Li J, Yang Z, et al.Impact of anatomical versus non-anatomical liver resection on short- and long-term outcomes for patients with intrahepatic cholangiocarcinoma[J].Ann Surg Oncol, 2019, 26(6):1841-1850.DOI: 10.1245/s10434-019-07260-8.
[22]
Endo I, Gonen M, Yopp AC, et al.Intrahepatic cholangiocarcinoma:rising frequency, improved survival, and determinants of outcome after resection[J].Ann Surg, 2008, 248(1): 84-96.DOI: 10.1097/SLA.0b013e318176c4d3.
[23]
Sotiropoulos GC, Bockhorn M, Sgourakis G, et al.R0 liver resections for primary malignant liver tumors in the noncirrhotic liver: a diagnosis-related analysis[J].Dig Dis Sci, 2009, 54(4): 887-894.DOI:10.1007/s10620-008-0408-6.
[24]
Tomimaru Y, Eguchi H, Wada H, et al.Surgical outcomes of liver resection combined with inferior vena cava resection and reconstruction with artificial vascular graft[J].Dig Surg, 2019, 36(6):502-508.DOI: 10.1159/000493434.
[25]
Reames BN, Ejaz A, Koerkamp BG, et al.Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis[J].J Surg Oncol,2017, 116(2): 133-139.DOI: 10.1002/jso.24633.
[26]
Zhang XF, Bagante F, Chakedis J, et al.Perioperative and long-term outcome for intrahepatic cholangiocarcinoma: impact of major versus minor hepatectomy[J].J Gastrointest Surg, 2017, 21(11): 1841-1850.DOI: 10.1007/s11605-017-3499-6.
[27]
Paul Wright G, Perkins S, Jones H, et al.Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: a comparison of surgical resection with intra-arterial therapies[J].Ann Surg Oncol, 2018, 25(1): 83-90.DOI: 10.1245/s10434-017-6110-1.
[28]
Franssen S, Soares KC, Jolissaint JS, et al.Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with multifocal intrahepatic cholangiocarcinoma[J].JAMA Surg, 2022,157(7): 590-596.DOI: 10.1001/jamasurg.2022.1298.
[29]
Yin L, Zhao S, Zhu H, et al.Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study[J].Sci Rep, 2021, 11(1): 12166.DOI:10.1038/s41598-021-91823-x.
[30]
Buettner S, Ten Cate DWG, Bagante F, et al.Survival after resection of multiple tumor foci of intrahepatic cholangiocarcinoma[J].J Gastrointest Surg, 2019, 23(11): 2239-2246.DOI: 10.1007/s11605-019-04184-2.
[31]
Li J, Moustafa M, Linecker M, et al.ALPPS for locally advanced intrahepatic cholangiocarcinoma: did aggressive surgery lead to the oncological benefit? an international multi-center study[J].Ann Surg Oncol, 2020, 27(5): 1372-1384.DOI: 10.1245/s10434-019-08192-z.
[32]
Fong ZV, Brownlee SA, Qadan M, et al.The clinical management of cholangiocarcinoma in the United States and Europe: a comprehensive and evidence-based comparison of guidelines[J].Ann Surg Oncol,2021, 28(5): 2660-2674.DOI: 10.1245/s10434-021-09671-y.
[33]
Benson AB, D’Angelica MI, Abbott DE, et al.Hepatobiliary cancers,version 2.2021, NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw, 2021, 19(5): 541-565.DOI: 10.6004/jnccn.2021.0022.
[34]
Group CW.Italian clinical practice guidelines on cholangiocarcinomapart Ⅱ: treatment[J].Dig Liver Dis, 2020, 52(12): 1430-1442.DOI: 10.1016/j.dld.2020.08.030.
[35]
中国抗癌协会肝癌专业委员会胆管癌协作组.原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)[J].中华消化外科杂志, 2022, 21(10): 1269-1301.DOI: 10.3760/cma.j.cn115610-20220829-00476.Chinese Society of Liver Cancer Cholangiocarcinoma Cooperative Group.Chinese expert consensus on management of intrahepatic cholangiocarcinoma (2022 edition)[J].Chin J Dig Surg, 2022, 21(10):1269-1301.DOI: 10.3760/cma.j.cn115610-20220829-00476.
[36]
Sposito C, Ratti F, Cucchetti A, et al.Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma[J].J Hepatol, 2023,78(2): 356-363.DOI: 10.1016/j.jhep.2022.10.021.
[37]
Rahim MK, Okholm TLH, Jones KB, et al.Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes[J].Cell, 2023, 186(6): 1127-1143.e18.DOI: 10.1016/j.cell.2023.02.021.
[38]
Sahara K, Tsilimigras DI, Merath K, et al.Therapeutic index associated with lymphadenectomy among patients with intrahepatic cholangiocarcinoma: which patients benefit the most from nodal evaluation?[J].Ann Surg Oncol, 2019, 26(9): 2959-2968.DOI:10.1245/s10434-019-07483-9.
[39]
Zhou R, Lu D, Li W, et al.Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma? A systematic review and meta-analysis[J].HPB, 2019, 21(7): 784-792.DOI: 10.1016/j.hpb.2018.12.011.
[40]
Zhang XF, Xue F, Dong DH, et al.Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis[J].Ann Surg, 2021, 274(6):e1187-e1195.DOI: 10.1097/SLA.0000000000003788.
[41]
Kim SH, Han DH, Choi GH, et al.Extent of lymph node dissection for accurate staging in intrahepatic cholangiocarcinoma[J].J Gastrointest Surg, 2022, 26(1): 70-76.DOI: 10.1007/s11605-021-05039-5.
[42]
Ratti F, Cipriani F, Ariotti R, et al.Safety and feasibility of laparoscopic liver resection with associated lymphadenectomy for intrahepatic cholangiocarcinoma: a propensity score-based casematched analysis from a single institution[J].Surg Endosc, 2016,30(5): 1999-2010.DOI: 10.1007/s00464-015-4430-4.
[43]
Lee W, Park JH, Kim JY, et al.Comparison of perioperative and oncologic outcomes between open and laparoscopic liver resection for intrahepatic cholangiocarcinoma[J].Surg Endosc, 2016, 30(11): 4835-4840.DOI: 10.1007/s00464-016-4817-x.
[44]
Kinoshita M, Kanazawa A, Takemura S, et al.Indications for laparoscopic liver resection of mass-forming intrahepatic cholangiocarcinoma[J].Asian J Endosc Surg, 2020, 13(1): 46-58.DOI: 10.1111/ases.12703.
[45]
Meyer CG, Penn I, James L.Liver transplantation for cholangiocarcinoma: results in 207 patients[J].Transplantation, 2000, 69(8):1633-1637.DOI: 10.1097/00007890-200004270-00019.
[46]
Sapisochin G, Facciuto M, Rubbia-Brandt L, et al.Liver transplantation for “very early” intrahepatic cholangiocarcinoma:International retrospective study supporting a prospective assessment[J].Hepatology, 2016, 64(4): 1178-1188.DOI: 10.1002/hep.28744.
[47]
De Martin E, Rayar M, Golse N, et al.Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis[J].Liver Transpl, 2020, 26(6): 785-798.DOI: 10.1002/lt.25737.
[48]
Lunsford KE, Javle M, Heyne K, et al.Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series[J].Lancet Gastroenterol Hepatol,2018, 3(5): 337-348.DOI: 10.1016/S2468-1253(18)30045-1.
[49]
Valle J, Wasan H, Palmer DH, et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J].N Engl J Med, 2010, 362(14):1273-1281.DOI: 10.1056/NEJMoa0908721.
[50]
Lee J, Park SH, Chang HM, et al.Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, openlabel, randomised, phase 3 study[J].Lancet Oncol, 2012, 13(2): 181-188.DOI: 10.1016/S1470-2045(11)70301-1.
[51]
Rimini M, Fornaro L, Lonardi S, et al.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data[J].Liver Int, 2023, 43(8): 1803-1812.DOI:10.1111/liv.15641.
[52]
Oh DY, He AR, Qin S, et al.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer[J].NEJM Evid, 2022, 1(8):EVIDoa2200015.DOI: 10.1056/EVIDoa2200015.
[53]
Kim ST, Kang JH, Lee J, et al.Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial[J].Ann Oncol, 2019, 30(5): 788-795.DOI:10.1093/annonc/mdz058.
[54]
Morizane C, Okusaka T, Mizusawa J, et al.Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase Ⅲclinical trial[J].Ann Oncol, 2019, 30(12): 1950-1958.DOI: 10.1093/annonc/mdz402.
[55]
Ioka T, Kanai M, Kobayashi S, et al.Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)[J].J Hepatobiliary Pancreat Sci, 2023, 30(1): 102-110.DOI: 10.1002/jhbp.1219.
[56]
Le Roy B, Gelli M, Pittau G, et al.Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J].Br J Surg,2018, 105(7): 839-847.DOI: 10.1002/bjs.10641.
[57]
Martin RCG 2nd, Simo KA, Hansen P, et al.Drug-eluting bead,irinotecan therapy of unresectable intrahepatic cholangiocarcinoma(DELTIC) with concomitant systemic gemcitabine and cisplatin[J].Ann Surg Oncol, 2022, 29(9): 5462-5473.DOI: 10.1245/s10434-022-11932-3.
[58]
Cercek A, Boerner T, Tan BR, et al.Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial[J].JAMA Oncol, 2020,6(1): 60-67.DOI: 10.1001/jamaoncol.2019.3718.
[59]
Geschwind JFH, Salem R, Carr BI, et al.Yttrium-90 microspheres for the treatment of hepatocellular carcinoma[J].Gastroenterology, 2004,127(5 Suppl 1): S194-S205.DOI: 10.1053/j.gastro.2004.09.034.
[60]
Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al.Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres:results from a pilot study[J].Cancer, 2008, 113(8): 2119-2128.DOI:10.1002/cncr.23818.
[61]
Edeline J, Touchefeu Y, Guiu B, et al.Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial[J].JAMA Oncol, 2020,6(1): 51-59.DOI: 10.1001/jamaoncol.2019.3702.
[62]
Sutton TL, Billingsley KG, Walker BS, et al.Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma[J].Am J Surg, 2021, 221(6): 1182-1187.DOI: 10.1016/j.amjsurg.2021.02.029.
[63]
Yadav S, Xie H, Bin-Riaz I, et al.Neoadjuvant vs.adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis[J].Eur J Surg Oncol, 2019, 45(8): 1432-1438.DOI: 10.1016/j.ejso.2019.03.023.
[64]
Mason MC, Massarweh NN, Tzeng CD, et al.Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? implications from the neoadjuvant experience[J].Ann Surg Oncol, 2021, 28(11):6725-6735.DOI: 10.1245/s10434-020-09536-w.
[65]
Maithel SK, Keilson JM, Cao HST, et al.NEO-GAP: a single-arm,phaseⅡfeasibility trial of neoadjuvant gemcitabine, cisplatin, and nabpaclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma[J].Ann Surg Oncol, 2023, 30(11): 6569-6570.DOI: 10.1245/s10434-023-13874-w.
[66]
Tsilimigras DI, Sahara K, Wu L, et al.Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches[J].JAMA Surg, 2020, 155(9): 823-831.DOI:10.1001/jamasurg.2020.1973.
[67]
Primrose JN, Fox RP, Palmer DH, et al.Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised,controlled, multicentre, phase 3 study[J].Lancet Oncol, 2019, 20(5):663-673.DOI: 10.1016/S1470-2045(18)30915-X.
[68]
Bridgewater J, Fletcher P, Palmer DH, et al.Long-term outcomes and exploratory analyses of the randomized phase Ⅲ BILCAP study[J].J Clin Oncol, 2022, 40(18): 2048-2057.DOI: 10.1200/JCO.21.02568.
[69]
Nakachi K, Ikeda M, Konishi M, et al.Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202,ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial[J].Lancet, 2023, 401(10372): 195-203.DOI: 10.1016/S0140-6736(22)02038-4.
[70]
Edeline J, Benabdelghani M, Bertaut A, et al.Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase Ⅲ study[J].J Clin Oncol, 2019, 37(8): 658-667.DOI: 10.1200/JCO.18.00050.
[71]
胡笛,黄金涛,仲斌演,等.肝内胆管癌的诊疗进展[J].临床肝胆病杂志,2024,40(7):1470-1476.DOI:10.12449/JCH240728.Hu D, Huang JT, Zhong BY,et al.Advances in the diagnosis and treatment of intrahepatic cholangiocarcinoma[J].J Clin Hepatol,2024,40(7):1470-1476.DOI:10.12449/JCH240728.
[72]
Oh DY, Lee KH, Lee DW, et al.Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, singlecentre, phase 2 study[J].Lancet Gastroenterol Hepatol, 2022, 7(6):522-532.DOI: 10.1016/S2468-1253(22)00043-7.
[73]
Abou-Alfa GK, Macarulla T, Javle MM, et al.Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study[J].Lancet Oncol, 2020, 21(6): 796-807.DOI: 10.1016/S1470-2045(20)30157-1.
[74]
Javle M, Roychowdhury S, Kelley RK, et al.Infigratinib (BGJ398)in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study[J].Lancet Gastroenterol Hepatol, 2021, 6(10): 803-815.DOI: 10.1016/S2468-1253(21)00196-5.
[75]
Boilève A, Verlingue L, Hollebecque A, et al.Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers[J].Expert Opin Investig Drugs, 2021, 30(4): 401-409.DOI: 10.1080/13543784.2021.1896703.
[76]
Zhu AX, Macarulla T, Javle MM, et al.Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial[J].JAMA Oncol, 2021, 7(11): 1669-1677.DOI: 10.1001/jamaoncol.2021.3836.
[1] 钟锴, 蒋铁民, 张瑞青, 吐尔干艾力·阿吉, 邵英梅, 郭强. 加速康复外科在肝囊型棘球蚴病肝切除术中的应用分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 425-429.
[2] 张小松, 马俊永, 李锡锋, 施乐华, 沈锋. 腹腔镜鞘内解剖性右半肝切除联合区域淋巴结清扫[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(03): 245-245.
[3] 韦洋, 赵远权, 王小波, 黄海, 陈洁. BCLC 0/A期肝细胞癌患者术后辅助治疗后早期复发风险分析及预测模型建立[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 157-161.
[4] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[5] 冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[6] 吴哲境, 李敬东, 熊永福, 刘刚, 陈雷. 吲哚菁绿在解剖性肝切除术中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 25-29.
[7] 马子慧, 郭卫星. 腹腔镜肝尾状叶切除术的临床应用[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 36-40.
[8] 黄忠晶, 张丽东, 伍子奕, 艾军华. 不可切除肝细胞癌的转化治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 41-45.
[9] 李家军, 万思乐, 陆朝阳. 肝中心型肿瘤切除术后胆漏临床分析[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 87-91.
[10] 李伟男, 杨刚, 熊永福, 李强, 李敬东. 中晚期肝癌TACE 联合靶向免疫转化治疗后成功实施ALPPS 的初步经验[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 97-101.
[11] 于毅, 谢敖文, 刘俊, 王攀, 何德剑, 彭欣然, 何章勇, 何玉成, 李琼, 李洪涛, 王国彦, 周建, 刘升辉, 王永军, 赵春博, 段清垚. 以指捏法切肝为核心技术的全流程管理在严重肝外伤中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 107-112.
[12] 蒙柄成, 朱海, 任洪冰, 毛伟民, 韦德令, 徐邦浩, 王继龙, 金宗睿, 蓝祝晶, 黄柯豫, 卢婷婷, 张灵, 郭雅, 文张. IGF-1 介导FOXO 信号通路在大鼠ALPPS 术后肝再生中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 118-125.
[13] 杭轶, 杨小勇, 李文美, 薛磊. 可控性低中心静脉压技术在肝切除术中应用的最适中心静脉压[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 813-817.
[14] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[15] 王闪闪, 赵海涛. 胆道癌转化手术策略[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(01): 1-5.
阅读次数
全文


摘要